Tuesday 13 October 2026
Export ARVN’s income statement to Excel — free account
Arvinas, Inc.
ARVN Healthcare Biotechnology
Arvinas, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $262.6 million, roughly unchanged from fiscal 2024. In the quarter to June 2026, revenue grew 1,014.7%, EPS grew 410.7%, free cash flow grew 49.8% and total debt fell 40.0%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
7.14
0.31
−4.16%
Follow ARVN
| Dec '16 | Dec '17 | Dec '18 | Dec '19 | Dec '20 | Dec '21 | Dec '22 | Dec '23 | Dec '24 | Dec '25 | |
|---|---|---|---|---|---|---|---|---|---|---|
P/E ratio |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Piotroski F-Score |
— | — | 2 | 5 | 4 | 4 | 3 | 3 | 3 | 5 |
P/S ratio |
0.00 | 0.00 | 8.45 | 31.44 | 129.53 | 76.62 | 13.51 | 32.30 | 5.23 | 3.20 |
Altman Z-Score |
— | — | (0.58) | 9.70 | 26.38 | 3.10 | 0.80 | 0.68 | 0.00 | (0.61) |
P/FCF ratio |
3.06 | 3.06 | 0.00 | 0.00 | 0.00 | 7.40 | 0.00 | 0.00 | 0.00 | 0.00 |
Altman Z″-Score (non-manufacturers) |
0.70 | (0.85) | 1.56 | 3.61 | 11.58 | 4.17 | 1.85 | 0.82 | 0.03 | (1.73) |
Beneish M-Score |
— | 9.54 | (3.29) | 27.56 | (2.30) | (2.65) | (2.01) | (2.65) | (0.22) | (1.60) |
P/Operating CF |
(2.50) | (2.50) | (9.88) | (83.70) | (115.82) | (115.04) | (24.93) | (30.51) | (16.39) | (27.66) |
P/B ratio |
0.00 | 0.00 | 0.89 | 5.96 | 5.22 | 5.25 | 3.14 | 3.84 | 2.45 | 1.94 |
Price to Tangible BV |
0.00 | 0.00 | 0.89 | 5.96 | 5.22 | 5.25 | 3.14 | 3.84 | 2.45 | 1.94 |
EV/Sales |
0.00 | 0.00 | (4.51) | 24.97 | 103.06 | 48.54 | 4.31 | 16.20 | 1.29 | 0.60 |
EV/EBITDA |
0.00 | 0.00 | 1.51 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
EV/Operating CF |
(0.38) | (0.38) | 4.01 | (26.44) | (29.76) | 4.65 | (2.07) | (3.66) | (1.31) | (0.57) |
EV/FCF |
(0.46) | (0.46) | 3.41 | (22.89) | (27.77) | 4.69 | (2.02) | (3.63) | (1.31) | (0.57) |
Quick Ratio |
3.68 | 3.65 | 8.39 | 8.75 | 14.17 | 5.86 | 4.13 | 4.95 | 4.58 | 4.85 |
Current Ratio |
3.72 | 3.67 | 8.52 | 8.86 | 14.29 | 5.93 | 4.20 | 4.98 | 4.64 | 4.92 |
Net Debt/EBITDA |
2.27 | 1.62 | 4.34 | 5.69 | 5.97 | 8.73 | 4.89 | 3.09 | 3.98 | 5.62 |
Debt/Assets |
1.20% | 0.46% | 1.08% | 0.66% | 0.28% | 0.06% | 0.08% | 0.06% | 0.05% | 0.06% |
Debt/Equity |
0.02 | 1.26 | 0.02 | 0.01 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Asset Turnover |
0.13 | 0.14 | 0.11 | 0.17 | 0.05 | 0.05 | 0.09 | 0.06 | 0.22 | 0.29 |
Operating CF/Net income |
1.57 | (0.18) | 0.07 | 0.58 | 0.75 | (2.93) | 0.97 | 0.95 | 1.30 | 3.39 |
Capex/Depreciation |
(0.26) | (1.43) | (2.91) | (2.52) | (1.10) | (0.30) | (0.43) | 0.34 | 0.16 | 0.58 |
Interest Coverage |
(244.35) | (491.28) | (763.10) | (515.00) | (33.69) | (104.67) | (21.93) | — | — | — |
| 26.32% | 60.82% | (635.93%) | (38.70%) | (27.46%) | (26.83%) | (41.96%) | (59.97%) | (32.56%) | (16.23%) | |
| (23.54%) | (54.63%) | (180.25%) | (28.07%) | (23.41%) | (16.62%) | (19.82%) | (28.55%) | (16.60%) | (8.93%) | |
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
Return on Tangible Assets |
(44.31%) | (58.44%) | (136.06%) | (26.38%) | (17.91%) | (14.65%) | (29.47%) | (35.50%) | (23.55%) | (14.34%) |
Average Days of Receivables |
77.18 | 1,254.11 | 128.22 | 53.31 | 118.38 | 175.01 | 22.22 | 33.48 | 18.98 | 8.90 |
Research and Development Expense of Revenue |
299.03% | 379.91% | 315.51% | 156.28% | 418.53% | 336.57% | 239.73% | 483.69% | 132.19% | 108.61% |
Selling, General and Administrative Expense of Revenue |
47.93% | 46.79% | 90.28% | 63.49% | 147.88% | 114.93% | 60.58% | 127.77% | 62.79% | 36.52% |
Intangible Assets out of Total Assets |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Share Based Compensation of Revenue |
7.88% | 3.23% | 81.20% | 46.74% | 116.60% | 106.53% | 57.46% | 91.21% | 33.49% | 16.76% |
Graham Net Nets |
1.22 | 1.22 | 1.10 | 0.16 | 0.19 | 0.18 | 0.30 | 0.25 | 0.39 | 0.50 |
Graham Number |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Earnings Yield |
(7.91%) | (7.91%) | (105.08%) | (5.14%) | (3.52%) | (4.64%) | (15.95%) | (15.66%) | (14.45%) | (10.79%) |
Free Cash Flow Yield |
32.67% | 32.67% | (15.65%) | (3.47%) | (2.86%) | 13.51% | (15.79%) | (13.83%) | (18.94%) | (32.79%) |
Revenue per Share |
3.51 | 4.00 | 1.52 | 1.31 | 0.66 | 1.07 | 2.47 | 1.41 | 3.66 | 3.70 |
Operating CF per Share |
(10.22) | 2.70 | (1.71) | (1.23) | (2.27) | 11.19 | (5.14) | (6.27) | (3.61) | (3.86) |
Capex per Share |
(0.14) | (0.53) | (0.30) | (0.19) | (0.16) | (0.09) | (0.13) | (0.05) | (0.02) | (0.03) |
Free Cash Flow per Share |
(10.36) | 2.16 | (2.01) | (1.43) | (2.43) | 11.09 | (5.27) | (6.32) | (3.63) | (3.89) |
Cash per Share |
18.73 | 20.65 | 19.93 | 8.54 | 17.43 | 30.14 | 22.76 | 22.82 | 14.46 | 9.67 |
Shareholders Equity per Share |
12.66 | 0.13 | 14.50 | 6.89 | 16.26 | 15.63 | 10.62 | 11.89 | 7.81 | 6.12 |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Book value per Share |
12.66 | 0.13 | 14.50 | 6.89 | 16.26 | 15.63 | 10.62 | 11.89 | 7.81 | 6.12 |
Free Cash Flow |
(19.66) | 4.10 | (18.95) | (46.90) | (96.10) | 554.70 | (280.30) | (350.70) | (261.00) | (275.70) |
Working Capital |
27.25 | 47.67 | 172.70 | 258.07 | 653.90 | 1,290.80 | 945.10 | 1,023.10 | 837.50 | 558.20 |
Capital Expenditures |
(0.26) | (1.01) | (2.83) | (6.30) | (6.40) | (4.70) | (6.80) | (2.90) | (1.70) | (1.90) |
Net Current Asset Value |
23.38 | (1.07) | 133.06 | 215.93 | 627.90 | 752.60 | 536.30 | 635.60 | 537.60 | 416.70 |
EV/EBIT |
0.00 | 0.00 | 1.47 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Capex to Sales |
0.04 | 0.13 | 0.20 | 0.15 | 0.25 | 0.09 | 0.05 | 0.04 | 0.01 | 0.01 |
Price to Operating Income |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Other line items | ||||||||||
Depreciation/Fixed assets |
1.53 | 0.55 | 0.27 | 0.30 | 0.47 | 1.24 | 1.17 | (0.75) | (1.51) | (0.63) |
Cash ROIC |
(32.74%) | 10.32% | (5.80%) | (9.20%) | (7.21%) | 24.22% | (15.78%) | (18.20%) | (16.30%) | (24.62%) |
Accounts Receivable Turnover |
0.49 | 0.55 | 0.92 | 7.60 | 3.53 | 3.14 | 7.80 | 10.33 | 25.21 | 26.13 |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Inventory Turnover |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Days of Inventory on Hand |
— | — | — | — | — | 0.00 | 0.00 | — | — | — |
Average Receivables |
13.71 | 13.73 | 15.54 | 5.66 | 7.34 | 17.05 | 16.85 | 7.60 | 10.45 | 10.05 |
Average Payables |
1.28 | 1.08 | 1.68 | 3.66 | 5.83 | 30.75 | 64.55 | 83.45 | 82.00 | 70.65 |
Average Assets |
52.47 | 52.39 | 133.07 | 250.46 | 509.52 | 1,149.50 | 1,425.20 | 1,286.70 | 1,198.00 | 904.65 |
Average Common Equity |
(46.94) | (47.06) | 37.72 | 181.68 | 434.44 | 711.95 | 673.30 | 612.45 | 610.85 | 497.80 |
Columns are period end dates